Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TLR4 | O00206 | 4/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720591 | 1.00 | TSHR (0.38) | TSHRMAPK1CES2MAPTTLR4 | |
| SCHEMBL2388827 | 1.00 | TSHR (0.38) | TSHRMAPK1CES2MAPTTLR4 | |
| SCHEMBL10008216 | 1.00 | TSHR (0.38) | TSHRMAPK1CES2MAPTTLR4 | |
| Phenylhydrazine SCHEMBL3087254 | 0.79 | CYP1A2 (0.40) | TDP1 | |
| SCHEMBL14099602 | 0.78 | MAPT (0.34) | MAPTTLR4 | |
| SCHEMBL1719695 | 0.74 | TSHR (0.43) | TSHRMAPK1KDM4EHTTTDP1 | |
| Beta-Pinene SCHEMBL900792 | 0.73 | TSHR (0.38) | TSHRMAPK1KDM4EHTTTDP1 | |
| (+)-Beta-Pinene SCHEMBL3506800 | 0.73 | TSHR (0.38) | TSHRMAPK1KDM4EHTTTDP1 | |
| Beta-Pinene SCHEMBL1636093 | 0.73 | TSHR (0.38) | TSHRMAPK1KDM4EHTTTDP1 | |
| Beta-Pinene SCHEMBL1532504 | 0.73 | TSHR (0.38) | TSHRMAPK1KDM4EHTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288063-A1 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288063-A1 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS | B2M, MRPL21, RCE1 | TSHR 3794/4885MAPK1 4390/4885CES2 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.